There is convincing epidemiological and experimental evidence that capsaicin, a potent natural transient receptor potential cation channel vanilloid member 1 (TRPV1) agonist, has anticancer activity. However, capsaicin cannot be given systemically in large doses, because of its induction of acute pain and neurological inflammation. MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator of TRPV1, if added together with capsaicin, but is ineffective, if given alone. Addition of MRS1477 evoked Ca 2+ signals in MCF7 breast cancer cells, but not in primary breast epithelial cells. This indicates that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 agonists. We investigated the effects of MRS1477 and capsaicin on cell viability, caspase-3 and -9 activities and reactive oxygen species production in MCF7 cells. The fraction of apoptotic cells was increased after 3 days incubation with capsaicin (10 μM) paralleled by increased reactive oxygen species production and caspase activity. These effects were even more pronounced, when cells were incubated with MRS1477 (2 μM) either alone or together with CAPS (10 μM). Capsazepine, a TRPV1 blocker, inhibited both the effect of capsaicin and MRS1477. Whole-cell patch clamp recordings revealed that capsaicinevoked TRPV1-mediated current density levels were increased after 3 days incubation with MRS1477 (2 μM). However, the tumor growth in MCF7 tumor-bearing immunodeficient mice was not significantly decreased after treatment with MRS1477 (10 mg/ kg body weight, i.p., injection twice a week). In conclusion, in view of a putative in vivo treatment with MRS1477 or similar compounds further optimization is required.
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Introduction
Malignant tumors often develop at sites of chronic tissue injury and repair, which have an important role in the pathogenesis of malignant disease, with chronic inflammation being the most important risk factor [1] . The inflammatory microenvironment contributes to tumor progression by supplying bioactive molecules, including growth factors, survival factors and extracellular matrix-modifying enzymes [2] . By creating their own inflammatory microenvironment, cancer cells increase their independency from the regulating signals from the body and block the normal healing process. In the "unfriendly" environment created by the cancer cells neither the tumor-bordering normal non-mutated epithelial cells nor the immune system may function properly [3] .
The transient receptor potential cation channel (TRP) vanilloid member 1 (TRPV1) is a subfamily member of TRP channels that trigger intracellular signaling by an increase of the intracellular free Ca 2+ concentration [Ca 2+ ] i , Activation is triggered by multiple pain-inducing stimuli including inflammatory endovanilloids, heat (37-42˚C), acids (pH<6.3) and pungent exovanilloids such as capsaicin (CAPS) or resiniferatoxin [4] [5] [6] [7] [8] . Endovanilloids are frequently produced in the "inflammatory soup"; anandamide, 12(S)-hydroxyeicosatetraenoic acid (12 (S)-HETE), and other lipoxygenase metabolites of arachidonic and linoleic acids serve as potent agonists of TRPV1 [5, 9, 10] . These products are also present in the tumor microenvironment [11, 12] .
Expression of TRPV1 channels in neoplastic breast tissue has been reported before [13, 14] , but little is known about the channel's physiological function and the likely pathological consequences in these neoplasms. It has been known for a long time -even before TRPV1 channels were discovered-that lipoxygenase products, now well-known endogenous agonists of TRPV1 channels, promote tumor growth [15] . On the other hand, virtually all pharmacological and molecular methods used to examine the function of these channels resulted in a decrease of cell viability. These methods included molecular up-or downregulation of the channels and activation or inhibition of channels with natural exogenous agonists or synthetic antagonists [13, 16, 17] . Strong and persistent activation of TRPV1 in sensory neurons by exogenous agonists leads to the elimination of TRPV1-expressing neurons due to a necrotic-type, overstimulation-based cytotoxicity [18] [19] [20] [21] . However, exogenous TRPV1 agonists, although reducing tumor cell viability at high concentrations in vitro [13, 17] , fail to induce the overstimulationbased cytotoxicity observed in pain-sensing neurons, even at lower concentrations [13] . Potent natural agonist such as CAPS and RTX generally cannot be given systemically or in large doses, since it produces acute pain, neurological inflammation and a decrease in the core body temperature [22, 23] .
One of the authors of this study had previously noted that MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator (PAM) of TRPV1, when added together with a TRPV1 agonist. Yet MRS1477 has little or no effect on cells expressing TRPV1 either endogenously or ectopically, if added alone [24] [25] [26] (for details, see Fig 1A) . MRS1477 was found I) to be a specific modulator of TRPV1 channels, in contrary to other dihydropyridine derivatives showing no allosteric effects on TRPV1 [24] , II) to further increase the sensitivity of TPRV1 already sensitized with low pH (6.0) or protein kinase C phosphorylation [26] and III) to modulate the effect of endogenously produced TRPV1 agonists [25] . MRS1477 did not affect channel inhibition by capsazepine, a competitive TRPV1 antagonist, indicating a distinct MRS1477 binding site on TRPV1 for positive allosteric modulation [26] .
Positive modulation of TRPV1 function(s) might lead to cytotoxicity, because excess activity of TRPV1 channels evokes not only necrotic processes with membrane bleb formation [16, 20] , but also apoptotic processes [27] . In addition, we reported recently that MCF7 cell ] i continuously decreased after the initial peak at approximately 2 min (orange curve). Statistically significant differences between the two curves (Student t-test, p<0.05) are marked with asterisks. C-I) Single responses in cancer cells [13, 32] ; the latter endogenously expressing much lower levels of TRPV1 than TRPV1+ neurons [13] . Of note, CAPS exerts TRPV1-independent effects, however at concentrations above 250 μM [33] . CAPS-induced necrotic processes can be evoked in cells expressing high levels of receptors such as TRPV1-positive pain-sensing neurons or cells ectopically expressing TRPV1 receptor. Nevertheless, cancer cells expressing lower levels of TRPV1 proteins [13] might be still sensitive to TRPV1-mediated apoptotic processes, possibly in the presence of a TRPV1 modulator as explained in Fig 1A. We hypothesized that the compound MRS1477 might be able to increase the oxidative stress levels in tumor cells expressing TRPV1 channels that are also producing endogenous TRPV1 agonists. Since in an otherwise healthy body TRPV1 agonists are only produced in the tumor microenvironment, PAMs of TRPV1 might have tumor-selective cytotoxic effects.
Materials and methods

Reagents
Capsaicin (CAPS), a TRPV1 agonist and capsazepine (CapZ), a well-characterized antagonist of TRPV1 were dissolved in DMSO at a concentration of 100 mM (all from Sigma-Aldrich, St. Louis, MO). 4-Ethyl-1,4-dihydro-5-[[(2-methoxyethyl)thio]carbonyl]-6-methyl-2-phenyl-3-yridinecarboxylic acid ethyl ester (MRS1477 or short MRS) was synthetized in Dept. of Chemistry, University of Miskolc, Miskolc, Hungary and was dissolved in DMSO at a concentration of 100 mM. 13(S)-hydroxyoctadeca-9Z,11E-dienoic (13(S)-HODE) and 8, 9-epoxyeicosatrienoic acids (8, 9-EET), both endogenous agonists of TRPV1 were obtained from Cayman Chemicals (Ann Arbor, MI, USA). Dihydrorhodamine-123 (DHR 123) and Trisglycine gels were from Molecular Probes (Eugene, OR, USA). Caspase substrates [N-acetylLeu-Glu-His-Asp-7-amino-4-methylcoumarin (AC-LEHD-AMC) and N-acetyl-Leu-GluHis-Asp-7-amino-4-methylcoumarin (AC-LEHD-AMC)] were purchased from Bachem (Bubendorf, Switzerland). A mitochondrial stain 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) was purchased from Santa Cruz (Dallas, TX, USA). Borosilicate capillary glass for patch-clamp experiments was purchased from Sutter Inc. (Novato, CA, USA). All organic solvents were purchased from Santa Cruz (Dallas, TX, USA). The reagents were equilibrated at room temperature for 30 min before any experiments.
Cell lines and cell extract
MCF7, MDA-MB-231 as well as BT-474 cells of human breast cancer origin (obtained from ATCC) were cultured in RPMI 1640 medium supplemented with fetal bovine serum in a humidified incubator at 37˚C, 5% CO 2 and 95% air. Non-transfected NIH-3T3 and NIH-3T3 murine fibroblast cells permanently expressing rat TRPV1 (NIH-3T3 TRPV1 ) were a kind gift from Dr. Zoltan Olah, Institute of Chemistry, University of Miskolc, Hungary. In NIH-3T3 TRPV1 cells, the metallothionein promoter is used to drive the expression of full-length rat TRPV1 containing additionally a short 12-amino acid ε-tag [21] . These cells express TRPV1 in their plasma membrane at high density and as such they may be used as an indicator cell line for the presence of vanilloids. Cells were cultivated in DMEM containing 10% fetal calf serum and antibiotics (penicillin and streptomycin) at 37˚C/5% CO 2 . Primary breast epithelial cells were isolated from fresh human milk and cultivated according to an established protocol [34] . Milk was diluted 1:1 with phosphate buffered saline (PBS). Milk cells were centrifuged, washed twice with PBS and cultivated in RPMI 1640 culture medium (Gibco Life Technologies, Grand Island, NY, USA), supplemented with 15% fetal bovine serum (Gibco), 10% human serum (Gibco), 1% penicillin-streptomycin (Gibco), 50 ng/ml cholera toxin (Sigma), 0.5 μg/ml hydrocortisone (Sigma), 1 μg/ml insulin (Sigma) at 37˚C in a humidified atmosphere (5% CO 2 , 95% air) [ responses of the entire cell population, the traces of more than 20 randomly selected cells were averaged and standard deviations (SD) were calculated. Each experimental procedure was repeated at least two times with similar results, but only one series of experiments is reported for each case. The LAS-AF (Leica, Wetzlar, Germany) and Prism3 (GraphPad Software, Inc., San Diego, CA) software were used for data analysis.
Groups for chronic treatment
The MCF7 cells were seeded in 8-10 flasks at a density of 1x10 6 ). All cells were cultured at 37˚C. The cells were divided into eight groups and all groups let to grow for 72 h in cell culture media containing the following compounds according to the Table 1. CAPS, CapZ and MRS were dissolved in DMSO and the pH was adjusted to pH = 7.4 by the addition of HCl. MRS1477 was prepared freshly, but CapZ and CAPS were stored at -33˚C. At the end of the treatments, all cells were used for the patch-clamp, apoptosis, cell viability, mitochondrial membrane depolarization, caspase and reactive oxygen species (ROS) assays.
Electrophysiology
Whole-cell recordings were performed using an EPC 10 amplifier equipped with a personal computer with Patchmaster software (HEKA, Lamprecht, Germany). The standard bath solution contained (in mM): 140 NaCl, 1. , 1 mM Cs-EGTA). MCF7 cells were held at a potential of -60 mV and current-voltage (I-V) relationships were obtained from voltage ramps from -90 to +60 mV applied for 400 ms. In the patch-clamp experiment MCF7 cells were perfused with standard bath solution containing CAPS (10 μM) for stimulation or CapZ for inhibition (0.1 mM). The pH of the solutions was adjusted just before starting of the experiments. All experiments were carried out at room temperature (21-23˚C). For the analysis the maximal current amplitudes (pA) in a cell were divided by the cell capacitance (pF), a measure of the cell surface. The resulting values represent the current density (pA/pF).
Cell viability (MTT) assay
To assess MRS' toxic effects on cell viability, we evaluated the mitochondrial activity of living cells by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) quantitative colorimetric assay. After treatment with CAPS and MRS, the cells were washed and incubated with fresh medium containing MTT (0.5 mg/ml) at 37˚C for 90 min. Then, the supernatant was discarded and DMSO was added to dissolve the formazan crystals. The absorbance in each well was measured at 650 nm using a microplate reader (Infinite Pro200; Tecan Austria GmbH, Groedig, Austria) [27] . We performed a total of 6 experiments (n = 6) for the cell viability assays. The data were presented as percentage relative to the control.
Assay for apoptosis markers
Apoptosis was evaluated using the APOPercentage Apoptosis Assay (Biocolor, Belfast, Northern Ireland) according to the manufacturer's instructions. In a viable cell, maintaining the asymmetric composition of membrane lipids is an energy-dependant process involving the activity of flipase enzymes. The loss of asymmetry serves as an early indicator of apoptosis. When the membrane of an apoptotic cell loses its asymmetry, the APOPercentage dye is actively transported into cells, staining apoptotic cells red, thus allowing detection of apoptosis by spectrophotometry. Absorbance was measured at 550 nm (Infinite Pro200). The data were presented as fold increase normalized to control. The determinations of caspase-3 and caspase-9 activities were based on a method previously reported [36] with minor modifications.
Cleavage of the caspase-3 substrate (AC-DEVD-AMC) and caspase-9 substrate (AC-LEH-D-AMC) was measured in a microplate reader (Infinite pro200) with an excitation wavelength of 360 nm and emission at 460 nm. The data were calculated as fluorescence units/mg protein and presented as fold increase normalized to control.
Intracellular ROS measurement
Dihydrorhodamine 123 (DHR 123) is a non-fluorescent, non-charged dye that easily penetrates cell membranes. Once inside the cell, DHR 123 gets fluorescent upon oxidation to yield rhodamine 123 (Rh 123), the fluorescence being proportional to ROS generation. The fluorescence intensity of Rh 123 was measured in a microplate reader (Infinite Pro200). Excitation was set at 488 nm and emission at 543 nm [27] . We performed a total of 6 experiments (n = 6) for the intracellular ROS assays. The data were presented as fold increase normalized to control.
Mitochondrial membrane potential determination
Cells were incubated with 1 μM JC-1 for 15 min at 37˚C as previously described [28] . JC-1 is a lipophilic, cationic dye that can selectively enter into mitochondria and reversibly change color from red to green as the mitochondrial potential decreases. The green signal was measured at an excitation wavelength of 485 nm and an emission wavelength of 535 nm, the red signal at an excitation wavelength of 540 nm and an emission wavelength of 590 nm. Fluorescence values were measured using the microplate reader Infinite Pro200 and the green/red fluorescence intensity ratio was calculated. The data were presented as fold increase normalized to control.
In vivo tumor growth experiment
In accordance with the 3R principles (S1 Text), animal studies were carried out on the basis of data from our in vitro experiments indicating that the treatment might be effective also in vivo.
The sample size calculations were based on the presumption that the treatment would result in a reduction of the average tumor size by at least 1. 
Statistical analysis
Data were analyzed using the Prism (Graphpad) program. All results are expressed as means ± SD. One-way ANOVA (ANalysis Of VAriance) with post-hoc Tukey HSD (Honestly Significant Difference) were performed for the results. P-values of less than 0.05 were regarded as significant.
Results
Acute effect of MRS1477 on the [Ca
2+
] i TRPV1 function may be assessed by its ability to pass Ca 2+ ions across the plasma membrane upon stimulation resulting in changes in [Ca 2+ ] i . The characteristics of positive allosteric modulators was observed in NIH-3T3 cells stably transfected with TRPV1 channel. This established cell line is highly sensitive to the presence of TRPV1 agonists and therefore may be used as an indicator cell line. MRS augmented the CAPS-evoked rises in [Ca 2+ ] i (Fig 1B, gray curve) , while MRS, administered alone, did not induce a Ca 2+ signal ( Fig 1C) . As a control, the cells were subsequently treated with CAPS that caused a rapid increase in [Ca 2+ ] i (Fig 1C) . CAPS (50 μM) induced a transient Ca 2+ signal in primary breast epithelial cells (Fig 1D) , while MRS (20 μM) administered alone did not have such an effect on these cells (Fig 1E) . A serumevoked Ca 2+ response was used as a control to show that cells were viable and moreover capable of a Ca 2+ response, when stimulated with an appropriate agonist (Fig 1E) . CAPS (50 μM), but more importantly also MRS alone (20 μM) evoked a Ca 2+ response in MCF7 cells (Fig 1F   and 1G ). We hypothesized that MCF7 cells responded to MRS as the result of the presence of endogenous TRPV1 agonists likely produced by MCF7 cells. To test this hypothesis we carried out a lipid extraction from MCF7 cells and this lipid extract diluted with DPBS (1:1000) was applied to either untransfected (control) or TRPV1-expressing NIH-3T3 cells. Untransfected cells did not respond to either MCF7 cell extracts or to 50 μM CAPS (Fig 1H) , while TRPV1-transfected cells showed Ca 2+ increases in response to both, i.e. lipophilic MCF7 cell extract and CAPS (50 μM) (Fig 1I) . These findings confirmed that endogenous TRPV1 agonists were produced by MCF7 cells. Next we tested the MRS effect on the Ca 2+ response evoked by previously identified endogenous TRPV1 agonists such as 13-HODE (1 μM) and 8,9-EET (1μM). In both cases, MRS augmented the agonist-evoked rises in [Ca 2+ ] i (Fig 1J and  1K) -extruding systems to cope with an excess of Ca 2+ ions entering the cell through TRPV1 channels may lead to apoptosis even few days later [28] . Thus, we continued our study with the examination of the chronic effects of MRS.
Effect of PAM pre-treatment on CAPS-induced TRPV1 currents in MCF7 cells
Cells from group 1 (control) and group 5 (MRS-treated) were used for electrophysiological experiments. As mentioned in the method section, holding potentials in the electrophysiological experiments were stable at -60 mV. There was no significant current in unstimulated cells (Fig 2A) . The TRPV1 channels in MCF7 cells from the control group were activated by CAPS (10 μM) (Fig 2B) . The currents induced by CAPS developed gradually (within 1.82 min) following the addition of CAPS to the medium and reached maximal amplitudes of up to 0.86 nA. We observed reversible and inhibitory effects of CapZ and NMDG + solutions on CAPSevoked currents (Fig 2B and 2C) . The mean values for the current densities (pA/pF) in the Group 1 (control) cells; without CAPS stimulation, with CAPS stimulation and with CapZ treatment after CAPS stimulation were 6 ± 3 (n = 3), 105 ± 12 (n = 3) and 37 ± 7 (n = 3), respectively ( Fig 2F) . Similar experiments were performed in cells from group 5 (MRS-treated) (Fig 2D and 2E) . The mean values for the current densities (pA/pF); without CAPS stimulation, with CAPS stimulation, with CapZ treatment after CAPS stimulation were 12 ± 3 (n = 3), 136 ± 19 (n = 4) and 37 ± 8 (n = 4), respectively (Fig 2F) . The comparison of the current density values of group 1 (control) and group 5 (MRS treated) after CAPS stimulation points to a significant effect of MRS pre-treatment on TRPV1 channels (Fig 2F) . However, the modulating effect by MRS on CAPS-evoked currents was relatively moderate: (%30% increase). (Fig 3A) . In order to test whether these differences were attributable to the different production rates of 13-HODE in the different cell lines, the relative amount of 13-HODE was determined using ELISA; however no significant differences were found between the cell lines (Fig 3B) . Serial dilutions of CAPS were applied to MCF7 cells to determine IC 50 values of CAPS, a specific TRPV1 agonist, in the presence and the absence of MRS. The determined IC 50 was 56 ± 12 μM for CAPS without MRS. In the presence of 2 μM MRS the IC 50 value for CAPS was more than 20-fold decreased to 2.4 ± 0.5 μM indicating a rather strong synergistic effect (Fig 3C) . To provide more evidence that a TRPV1-mediated pathway is involved in the toxic effect of MRS, the effects of CAPS, CapZ and MRS on MCF7 MTT assays were performed; each dot represent mean + SD and n = 6 samples (2 independent experiments in triplicates) D. Cells were incubated with CAPS (10 μM), CapZ (0.1 mM) or both with and without MRS (2 μM) for 72 h and then MTT assays were performed. The columns represent mean + SD and n = 6 (2 independent experiments in triplicates). The letters denote the following: a-significant difference from control group, b-significant difference from CAPS group, csignificant difference from CapZ group, d-significant difference from CAPS+CapZ group, e-significant difference from MRS group, f-significant difference from MRS+CAPS group and g-significant difference from MRS+CapZ group.
Effect of MRS treatment on the viability of cancer cells
https://doi.org/10.1371/journal.pone.0179950.g003
TRPV1, inflammation and tumor environment cell viability was determined 72 h post-treatment (Fig 3D) . While neither CAPS at the chosen concentration nor CapZ alone, nor the combination of the two had an effect on MCF7 viability, MRS (2 μM) significantly decreased (p<0.05) cell viability and it was even further decreased when combining MRS and CAPS (p<0.001). As expected, the viability-decreasing effect of MRS alone could not be rescued by CapZ treatment, since CapZ acts on the extracellular TRPV1 activator site, while MRS acts on the modulatory intracellular PAM site (Fig 1A) . In cells treated with MRS and CAPS, co-addition of CapZ slightly increased cell viability; however the viability was still lower than in cells treated with MRS only. This signifies that likely the concentration of CapZ was not sufficient to completely protect from the CAPS-mediated decrease in cell viability (Fig 3D) . In summary, this data showed that a TRPV1-mediated pathway is involved in the toxic effect of MRS.
Effect of MRS treatment on the activation of apoptotic pathways
The effects of CAPS, CapZ and/or MRS on apoptosis were determined in two independent ways: by determination of the loss of the plasma membrane asymmetry and by measuring the increased caspase activities (Fig 4A and 4B , respectively). Data analyses of the two complementary methods resulted in a rather congruent picture. A loss of membrane asymmetry (higher APOP values) and increased activities of caspase-3 and caspase-9 were observed in the CAPS and MRS groups; values were even higher in the group treated with both, CAPS+MRS. However, normalized values (to control) were also significantly (p<0.05) decreased when CapZ, a TRPV1 inhibitor, was added to the solution during incubation. In addition, all values of the apoptosis markers were further increased in the MRS+CAPS group compared to the CAPS only or MRS only groups (p<0.05). These results indicate an involvement of MRS in the activation of the (likely intrinsic) apoptotic pathway, since activation of caspase-3 (intrinsic) and caspase-9 (intrinsic + extrinsic) pathways were in almost all cases of similar magnitude.
Effect of MRS treatment on ROS production and mitochondrial membrane depolarization
Most Ca 2+ ions entering a cell caused by hyper-activity of TRPV1 channels are taken up into mitochondria [13] . Subsequently, mitochondrial Ca 2+ accumulation leads to mitochondrial depolarization, i.e. the mitochondrial membrane potential (C m ) diminishes resulting in an increase in intracellular ROS production and oxidative stress [39] . Mitochondrial membrane depolarization (estimated by the JC-1 assay and reported as a ratio) and ROS production (estimated by the DHR assay) were unaffected by CAPS alone; accordingly, the addition of CapZ or the combination of both had also no effect on mitochondrial membrane potential and ROS production (Fig 5) . On the contrary, in all groups subjected to a MRS treatment (MRS, MRS +CAPS, MRS+CapZ, MRS+CAPS+CapZ) values for both measurements were significantly increased (p<0.001) compared to the control group. The essentially unchanged values for MRS compared to MRS + CAPS indicated that the effect was mostly mediated by MRS. Addition of CapZ (MRS + CapZ group), assumed to essentially block the effects of CAPS, partially restored (decreased) the values for mitochondrial membrane depolarization and ROS production (p<0.05) compared to the MRS+CAPS group. In addition, these values were also higher in the MRS+CAPS group compared to the CAPS only group (p<0.001; for more details, see Fig 5) . These results point towards a significant effect of MRS on mitochondrial activity and oxidative stress. Moreover, it supports the presence of an endogenous activator of TRPV1 channels produced by MCF7 cells that is strongly modulated by MRS, but most likely not via the CAPS-binding site.
In vivo treatment of MCF7 tumors with MRS
Based on the rather strong effects of MRS on MCF7 cells in vitro, i.e. a decrease in cell viability, an increase in apoptosis and larger production of ROS, we assessed the putative antitumor capacity of MRS in a mouse model in vivo. C57Bl/6J mice (n = 5 animals) were treated with MRS (100 mg/ kg body weight) intraperitoneally, twice per week, in order to check for general in vivo toxicity; no apparent toxic effects were observed (e.g. no behavioral alterations, signs of pain (fur, posture) or animal death). In a following experiment, NSG mice (n = 5 animals per group) were injected with MCF7 cells (2 x 10 6 cells; s.c). After 7.5 days of unrestricted tumor growth, one group was treated with MRS (10 mg/kg body weight;, i.p., twice per week), the other group was treated with vehicle (saline). The tumor growth was estimated by caliper measurements in both groups during a total of 8 weeks after MRS treatment. No significant differences in tumor size were observed between the two groups (Fig 6A) . Also the macroscopic appearance of the tumors (shape, color, vascularization) was not different in the sham-treated vs. MRS-treated mice (Fig 6B) .
Discussion
Activation of TRPV1 channels with endo-and exovanilloids leads to pain sensation; moreover excessive and/or prolonged activation may lead to axonal destruction or even cell death of . Cells were incubated with CAPS (10 μM), CapZ (0.1 mM) or both with or without MRS (2 μM) for 72 h. Cells were then subjected to the APOPercentage TM assay (indicating the loss of plasma membrane lipid asymmetry) and to caspase activity assays. The letters denote the following: a-significant difference from control group, b-significant difference from CAPS group, c-significant difference from CapZ group, d-significant difference from CAPS+CapZ group, e-significant difference from MRS group, fsignificant difference from MRS+CAPS group and g-significant difference from MRS+CapZ group. nociceptive neurons and may evoke various biological responses in non-neural cell types [5, 13, 33, 40] . Endogenous TRPV1 ligands have likely different pharmacological properties (e.g. affinity, potency, metabolic rate, etc.) compared to naturally occurring exogenous agonists such as CAPS or RTX and consequently endogenous ligands might have different physiological functions. As an example, endogenous agonists are involved in the generation of chronic . Cells were incubated with CAPS (10 μM), CapZ (0.1 mM) or both, with or without MRS (2 μM) for 72 h. Then they were subjected to the DHR 123 and JC-1 assays indicating the levels of ROS production and mitochondrial membrane potential, respectively. The letters denote the following: a-significant difference from control group, b-significant difference from CAPS group, c-significant difference from CapZ group, d-significant difference from CAPS+CapZ group, e-significant difference from MRS group, f-significant difference from MRS+CAPS group and g-significant difference from MRS+CapZ group.
https://doi.org/10.1371/journal.pone.0179950.g005 TRPV1, inflammation and tumor environment pain, while exogenous agonists are capable of alleviating chronic pain due to the process of desensitization [41] . Similarly, although the tumor environment was shown to contain endogenous TRPV1 agonists promoting the development of tumors [42] , exogenous agonists such as CAPS might have an opposite, i.e. anti-tumorigenic effect. Beneficial effects of CAPS for the treatment of prostate cancer in vivo have been reported before. A prostate cancer patient, who ingested chili sauce twice a week maintained a stable prostate-specific antigen (PSA) reading for a year [43] ; PSA is an established marker for the presence and activity of prostate tumors. An oral dose of CAPS (5mg/kg b.w./day) significantly slowed down the growth of PC-3 prostate cancer xenografts in in vivo mouse models [44, 45] . A large cohort study revealed that consumption of spicy food is inversely correlated with the mortality caused by cancer, ischemic heart diseases and respiratory diseases [46] . The mechanism of how tumor cells are influenced by CAPS consumption is not entirely known. The two proposed mechanisms include I) that CAPS might interfere with the endogenous weaker agonists present in the tumor milieu or II) that CAPS influences the tumor innervation by sensory neurons.
Upregulation of TRPV1 channels in neoplastic breast and prostate tissue compared to normal tissue has been reported before [47, 48] , but tumors express lower levels of TRPV1 than sensory neurons [13] . Results from our experiments indicate that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 ligands based on our findings that I) in MCF7 cells, MRS caused a transient increase in [Ca 2+ ] i , while not in the other cell lines tested. II) In a previous study we had found that in MCF7 cells merely the overexpression of TRPV1 channels decreased the viability of cancer cells [13] . We observed that mainly apoptotic processes were activated, but also mitotic arrest in MCF7 GFP-TRPV1 cells was detected. The absence of mitosis in the surviving MCF7 GFP-TRPV1 cells subsequently didn't allow for the establishment of stable MCF7 GFP-TRPV1 clones, although we had been successful to establish cell clones permanently expressing ectopic TRPV1 protein using non-tumor derived cell lines such as HaCaT, a spontaneously immortalized keratinocyte cell line from adult human skin [33], or NIH-3T3 cells, a spontaneously immortalized mouse embryo fibroblast cell line [49] . Nevertheless, this phenomenon might be explained by the production of endogenous TRPV1 agonists, constantly activating the ectopically expressed TRPV1 channels in MCF7 cells. Here, we showed that a lipophilic extract from MCF7 cells must contain at least one TRPV1 agonist, because one (or several) components of the lipophilic extract was capable of activating the TRPV1 receptor. The presence of 13-HODE was identified (Fig 3C) but certainly other known or yet unknown endogenous TRPV1 agonists [50] are likely to be present in the lipophilic extract, whose molecular identification will require further studies. Nevertheless some predictions can be made based on previous studies. The oxidized linoleic acid metabolite 13-S-hydroxyoctadecadienoic acid (13-HODE) is present in human prostate adenocarcinoma specimens, while it is absent in adjacent normal tissue [51] . Also a low pH in the extracellular milieu activates TRPV1 [8, 52] and is associated with inflammation and the cancer microenvironment [53, 54] . LNCaP prostate cancer cells produce high amounts of 20-hydroxyeicosatetraeonic acid (20-HETE) [55] , another identified endogenous activator of TRPV1 channels [56] . Expression of 12-lipoxygenase, the enzyme involved in generation of 12(S)-HETE, is correlated with more malignant stages of prostate cancer [57, 58] ; 12(S)-HETE is a well-known endo-agonist ligand of TRPV1, shown to increase the firing rate of sensory neurons via activation of the TRPV1 channel opening [59] .
In our study, we applied the positive allosteric modulator (PAM) concept knowing that PAM alone, in our case MRS, does not have an intrinsic activity on TRPV1 channels [26] unlike exogenous vanilloid agonists or antagonists. MRS does not induce pain similar to TRPV1 agonists acting on pain sensing neurons [25] . The action of PAMs, such as MRS and MRS-analogs, are restricted to the site of the production of endogenous agonists of TRPV1; i.e. most probably specific to the inflammatory milieu of the proximal tumor environment. Here we demonstrated that MRS does not interfere directly with TRPV1 function, e.g. as shown by the absence of any increase in [Ca 2+ ] i in TRPV1-expressing NIH-3T3 cells (Fig 1C) . -extruding systems might be unable to cope with it. This in turn leads to intracellular ROS production and mitochondrial membrane depolarization [27] . Mounting evidence indicates that production of excessive ROS and stimulation of apoptotic pathways, including caspase-3 and -9 activities, are increased in MCF7 cells by increased mitochondrial membrane depolarization [28, 60] . Our results support the hypothesis that CAPS-and MRS-induced elevated Ca 2+ influx leads to mitochondrial membrane depolarization, excessive ROS production and apoptosis. Although a previous study had shown that MRS is a specific and cognate modulator of TRPV1 channels [24] , the fact that a relatively modest (30%) increase in Ca 2+ influx results in a huge change of mitochondrial functions raises the possibility that MRS has an off-target effect on a mitochondrial protein involved in mitochondrial Ca 2+ regulation.
In our in vivo study, however, we have not tested whether co-application of e.g. CAPS together with MRS would act synergistically and promote anti-tumor activity. We assumed that endogenous TRPV1 activators together with MRS might be sufficient to impair MCF7 tumor formation. It appears that the used concentration and/or the pharmacokinetic properties of MRS compound are not appropriate to impair tumor growth in vivo (Fig 6) .
In conclusion, this study's results indicated that MRS1477 alone or together with CAPS has an apoptotic effect on MCF7 breast cancer cells in in vitro assays. This might be related to upregulation of Ca 2+ entry, intracellular ROS production, caspase-3 and caspase-9 activities.
Although administered alone MRS1477 did not show significant antitumor activity, it still might be useful in combination with low dose of CAPS or with cytostatic compounds such as cisplatin. Future experiments should aim to find a combination of CAPS and various PAMs that might result in tumor regression in vivo without detrimental effects on the normal nontransformed cells also expressing TRPV1. Thus, despite of the promising in vitro results, further optimizations for a putative cancer treatment in vivo are required.
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